Centanafadine (Simtriyo^(®), 3) is a recently approved therapy for attention-deficit/hyperactivity disorder (ADHD) that introduces a first-in-class triple reuptake inhibition mechanism. Featuring a naphthyl group and a rigid azabicyclic scaffold, centanafadine functions as a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) with a potency profile of NET > DAT > SERT. Unlike flexible phenethylamine stimulants such as (meth)amphetamine (1), which enter presynaptic neurons and…
